Impact of Distress Level, Sleep Quality and Occlusal Trauma on Periodontal Status Among Bruxers

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30-45
SponsorPostgraduate Institute of Dental Sciences Rohtak

About this trial

Increased distress levels and impaired sleep quality are known to exacerbate bruxism by enhancing masticatory muscle activity, leading to excessive and prolonged occlusal forces. These abnormal forces may result in occlusal trauma, which can compromise the adaptive capacity of the periodontal tissues by increasing tooth mobility, widening the periodontal ligament space, and accelerating alveolar bone loss, particularly in the presence of existing periodontal inflammation. Although occlusal trauma alone may not initiate periodontal disease, it can act as an important modifying factor in disease progression. Despite the recognized individual associations of distress, sleep quality, bruxism, and periodontal health, limited evidence exists regarding their combined impact on periodontal status among bruxers. Therefore, evaluating the influence of distress level, sleep quality, and occlusal trauma on periodontal status is essential to better understand disease progression and to facilitate comprehensive, multidisciplinary management strategies for individuals with bruxism.

Eligibility criteria

Qualifiers

Adults aged 30-45 years

Patients diagnosed with periodontitis according to the 2017 World Workshop classification of periodontal and peri-implant diseases and conditions.

Patients who are probable bruxers according to BRUXSCREEN-Q

Minimum of 20 natural teeth

Disqualifiers

Systemic conditions affecting periodontium (e.g., diabetes, auto immune disorders)

History of drugs having the potential impact on periodontal status like phenytoin, cyclosporin, calcium-channel blockers or antidepressant drugs

Patients with pulpal pathology

Pregnant or lactating females

Trial design

Treatments tested in this trial

  • Pittsburgh Sleep Quality Index (PSQI)

Treatment groups

128 Participants
are divided into 2 treatment groups

Locations

This trial has no locations